Loading
Latest filing published 05 Apr 2022 for Enanta Pharmaceuticals INC, €454k. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Nathalie Adda discloses dealings in Enanta Pharmaceuticals Inc to SEC (Form 4). Over a trading history stretching from 8 October 2021 to 1 April 2022, the count stands at 8 filings.
Not one of the filings records a straightforward purchase or sale on the market. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
The record was last updated on 5 April 2022 with an option exercise (€454k) in Enanta Pharmaceuticals Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
8 of 8 declarations